Quince Therapeutics (NASDAQ:QNCX) Upgraded at EF Hutton Acquisition Co. I

Quince Therapeutics (NASDAQ:QNCX) was upgraded by equities researchers at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.

Quince Therapeutics Price Performance

Shares of NASDAQ QNCX opened at $0.85 on Tuesday. The firm has a 50-day simple moving average of $0.72 and a 200-day simple moving average of $0.80. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $36.73 million, a price-to-earnings ratio of -1.12 and a beta of 0.86. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $1.43.

Quince Therapeutics (NASDAQ:QNCX) last released its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter.

Insider Activity

In other news, President Charles S. Ryan acquired 48,387 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average cost of $0.65 per share, for a total transaction of $31,451.55. Following the completion of the transaction, the president now owns 122,461 shares in the company, valued at approximately $79,599.65. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Quince Therapeutics news, CEO Dirk Thye purchased 77,500 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were acquired at an average price of $0.69 per share, with a total value of $53,475.00. Following the purchase, the chief executive officer now directly owns 766,941 shares in the company, valued at approximately $529,189.29. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Charles S. Ryan purchased 48,387 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average price of $0.65 per share, with a total value of $31,451.55. Following the completion of the transaction, the president now owns 122,461 shares of the company’s stock, valued at approximately $79,599.65. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 158,887 shares of company stock valued at $105,609. 16.80% of the stock is currently owned by insiders.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.